SCHEMBL2908802

SCHEMBL2908802

COc1cc(N(Cc2cccnc2)c2cccc(Cl)c2)ccc1C(N)=O

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MKNK1 Q9BUB5 4/20 0.53
MKNK2 Q9HBH9 4/20 0.53
CCNE1 P24864 1/20 0.44
CDK2 P24941 1/20 0.44
PDK1 Q15118 7/20 0.44
PDK2 Q15119 1/20 0.44
PDK3 Q15120 1/20 0.44
PDK4 Q16654 1/20 0.44
RECQL P46063 1/20 0.43
HCRTR1 O43613 1/20 0.42
HCRTR2 O43614 1/20 0.42
QPCT Q16769 1/20 0.41
PDE4A P27815 1/20 0.41
PDE4B Q07343 1/20 0.41
PDE4C Q08493 1/20 0.41
PDE4D Q08499 1/20 0.41
ADRA1D P25100 1/20 0.41
MAPK1 P28482 1/20 0.41
GFER P55789 1/20 0.41
GRM5 P41594 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2904970 0.92 MKNK1 (0.45) MKNK1MKNK2PDK1PDK2PDK3
SCHEMBL2909456 0.91 PDK1 (0.44) MKNK1MKNK2PDK1PDK2PDK3
SCHEMBL2903452 0.90 PDK1 (0.45) PDK1PDK2PDK3PDK4RECQL
SCHEMBL2905903 0.87 MKNK1 (0.52) MKNK1MKNK2CCNE1CDK2PDK1
SCHEMBL2910673 0.84 CYP1A2 (0.45) PDK1PDK2PDK3PDK4RECQL
SCHEMBL2908204 0.83 MKNK1 (0.48) MKNK1MKNK2CCNE1CDK2PDK1
SCHEMBL1157430 0.83 MAPK1 (0.46) PDK1PDK2PDK3PDK4PDE4A
SCHEMBL1157440 0.81 MAPK1 (0.43) HCRTR1HCRTR2QPCTPDE4APDE4B
SCHEMBL1157376 0.80 PDE4B (0.43) HCRTR1HCRTR2QPCTPDE4APDE4B
SCHEMBL5407124 0.80 LMNA (0.41) PDK1PDK2PDK3PDK4PDE4A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20050222207-A1 Phosphodiesterase 4 inhibitors, including N-substituted diarylamine analogs MEMORY PHARMACEUTICAL CORPORATION 2005-10-06 US claimed
EP-1692109-B1 PHOSPHODIESTERASE 4 INHIBITORS, INCLUDING N-SUBSTITUTED DIARYLAMINE ANALOGS MEMORY PHARM CORP (US) 2010-08-18 EP disclosed
US-20050222207-A1 Phosphodiesterase 4 inhibitors, including N-substituted diarylamine analogs MEMORY PHARMACEUTICAL CORPORATION 2005-10-06 US disclosed
WO-2005061458-A2 PHOSPHODIESTERASE 4 INHIBITORS, INCLUDING N-SUBSTITUTED DIARYLAMINE ANALOGS MEMORY PHARMACEUTICALS CORPORATION (US) 2005-07-07 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050222207-A1 Phosphodiesterase 4 inhibitors, including N-substituted diarylamine analogs PDE4A, PDE4B, PDE3B MKNK1 4229/4885MKNK2 4117/4885CCNE1 1566/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.